IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ: ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced the first presentation of initial outcomes with up to two-year patient follow-up from its Powerlink Suprarenal Proximal Extension trial at the Society for Clinical Vascular Surgery’s 37th Annual Symposium in Ft. Lauderdale, Fla. The presentation entitled, “EVAR Using an Anatomical Fixation Technique with Suprarenal Orientation: Results of a Prospective, Multicenter Trial,” was delivered by principal investigator and lead enroller Stuart A. Harlin, M.D., FACS of Sacred Heart Medical Center in Pensacola, Fla.
